The study reports the presence of mutations in ARV-naive patients and genetic diversity of HIV-1 variants that circulate in Benin. Globally, the prevalence of transmitted drug resistance was 10,89% after 17 years of ARV circulation in the city, that is consistent with results from other African countries in which prevalence rates are also higher than 10% [7, 17-19]. But, studies from some others Sub-Saharan countries have reported rates lower than 10%, by using the same WHO standard protocol and the WHO list of resistance mutations for epidemiological surveys [20, 21]. HIV-1 drug resistance mutations were known to be one of the major factors limiting the effectiveness of ARVs. In our study, the mutations encountered were those associated with the ARVs used in first-line treatment since the start of the IBAARV (Beninese initiative for access to antiretroviral) in 2002. This first-line treatment used two NRTIs (AZT/D4T + 3TC) plus a NNRTI (NVP/EFV), NNRTI as well as non-boosted protease inhibitor (indinavir) regimens [22]. At that time, virologic monitoring was not available and patients were followed based on clinical signs and CD4 counts [23]. Moreover those who were in therapeutic failure stayed long periods of time with an ineffective treatment, leading to an accumulation of resistance mutations [24]. This accumulation of resistance mutations may compromise the effectiveness of second line drugs [25] and increases the risk of transmission of drug resistant strains to naïve patients [7]. Among naïve patients in our study, 27 already harboured at least one drug resistance mutations and the NNRTIs represent 10% while the NRTIs and PIs represent 6% and 1% respectively.
NRTIs resistance-associated mutations were present in sixteen patients. M184V was the predominant NRTI encountered which confers resistance to lamivudine (3TC). The K65R confers resistance to abacavir (ABC) and tenofovir (TDF). Thymidine-associated mutations (TAMs) were found but only one patient in our study harboured at least two TAMs conferring intermediate resistance to zidovudine (AZT). TAMs M41L, T215S have been described in Togo [7, 19] and also in Burkina Faso with D67N and K219Q [19]. K70R was observed in one case in our study was also found in Guinea-Conakry [21]. For non-adherence reasons to treatment, M184IV is quickly selected in patients under 3TC which explains its presence in high proportion in studies of transmitted resistance [20, 21]. Since the study was conducted after the time of TDF use (replacing D4T as recommended by WHO), the presence of K65R in patients could easily be explained.
The major mutations associated to NNRTIs were K103N (33%) encountered in fourteen patients which compromise effectiveness of NNRTIs first generation (NVP and EFV) and G190A (7%) identified in three patients which compromise nevirapine, efavirenz and etravirine [26]. These mutations associated with high-level resistance have been described in one and four patients in Togo and Conakry [7, 21] respectively in naïve patients. The others mutations excepting Y181C and Y188L detected in two cases were V106A, P225H, and V106M, each detected in one case.
Mutations V106A, Y188L, V106M are associated with high-level resistance to NVP and EFV while Y188L and both Y188L and V106A are associated with high-level resistance to rilpivirine (RPV) and to third NNRTI generation doravirine (DOR) respectively. The Y188L and both V106M and P225H are also associated with intermediate resistance to ETR and DOR while only P225H is associated with intermediate resistance to both NVP and EFV.
Two people exhibited each one mutations associated to PIs (I85V, n=1) and (L90M, n=1). In our study, none patient harboured both mutations which conferred intermediate resistance to atazanavir.
Globally, the presence of these mutations could be explained by the large use of Triomune which contains stavudine, lamivudine and nevirapine, and the use of Efavirenz, zidovudine and Indinavir in first-line therapy in Benin.
Phylogenetic analysis evidenced eight recent and three probable older transmission chains (6.5-8.9% of the study patients), reflecting active ongoing transmission. Interestingly, 8 patients reported as being MSM and from them, two were involved into the same transmission chain, in which one patient came from Togo and the second one was from Benin. Studies on MSM in Africa also evidenced behavioral links with heterosexual networks, in such a way that the MSM population could serve as a bridge for intermixing of HIV-1 variants
between low-risk women and high-risk men. This situation was described in Dakar where the subtype C predominating in the MSM group is increasing in the general population [27, 28], confirming the existence of a dual epidemic in the country. In our study we did not find any transmission chain involving both population groups individuals, however the number of MSM patients is too low to conclude. Obviously further studies are needed in key groups in order to assess whether HIV-1 strains from MSM intermix with those from the general population in Benin or with those from other countries.
In our study, the CRF02_AG predominated with 66.5% rate. Overall, the genetic diversity in Benin matches with results found in a neighboring country, Togo [7]. The other strains (CRF06_cpx, subtype G and sub-subtype A3) have been also reported in other neighbouring African countries [6, 20, 29]. Regarding the unique recombinants (URFs), their proportion among different regions have changed over time [30]. The rate observed in our study (15.7%, 39/248) is fully concordant with the proportion from West Africa [30] and is not significantly different from that was observed in Togo (22.9%, 19/83) (p = 0.27) [7]. These URFs being composed of predominant or co-circulating strains, demonstrate the existence of frequent dual infections with at least two strains of HIV-1 in the country.